Nonclinical Validation of the NexPTM Half-Life Extension Platform Using Human Growth Hormone as a Model Therapeutic Protein

Abstract NexP™ is a proprietary carrier platform engineered from human alpha-1 antitrypsin (A1AT) to extend the systemic exposure of therapeutic proteins while retaining biological activity. The NexP™ scaffold incorporates an additional N-linked glycosylation site and a mutation in the reactive center loop designed to reduce its intrinsic protease inhibitory activity. Human growth hormone (hGH) was selected as a model therapeutic protein to evaluate the pharmacological performance, safety profile, and developability of the NexP™ platform. ALT-P1, a long-acting hGH candidate, containing NexP™ at its C-terminus of hGH, was produced in mammalian cells and purified by a series of column chromatography steps. The purified protein was characterized Human growth hormone (hGH) was selected as a model therapeutic protein to evaluate the pharmacological properties, nonclinical safety, and developability of this platform. ALT-P1, an hGH fusion protein containing NexP™ at its C-terminus, was produced in mammalian cells and purified using chromatographic methods. ALT-P1 was characterized by physicochemical analyses, including SDS-PAGE, isoelectric focusing, size-exclusion chromatography, N-linked glycan profiling, and circular dichroism (CD) spectroscopy. Binding affinity for the human growth hormone receptor and in vitro activity were further assessed by receptor-binding, MTS-based cell proliferation and luciferase reporter assays. Pharmacokinetic, pharmacodynamic, and toxicological profiles were evaluated in Sprague-Dawley rats and cynomolgus monkeys. Systemic exposure to ALT-P1 increased with increasing subcutaneous doses in rats, and pharmacokinetic studies demonstrated sustained systemic exposure in both species. ALT-P1 increased serum insulin-like growth factor I (IGF-1) levels in cynomolgus monkeys and promoted body weight gain and tibial growth in hypophysectomized rats. In a 26 week repeated-dose toxicity study in cynomolgus monkeys, ALT-P1 was generally well tolerated, with a no-observed-adverse-effect level (NOAEL) of 20 mg/kg, the highest dose tested. A GMP-manufactured clinical batch maintained its quality attributes and biological potency during long-term storage. Collectively, these findings support the further development of ALT-P1 as a long-acting hGH candidate and suggest the potential applicability of NexP™ as a half-life-extension platform for other biologic therapeutics.

Authors

Institutions

Publication Details

Journal
Molecular Pharmaceutics
Published
2026-11-17
DOI
https://doi.org/10.1021/acs.molpharmaceut.6c01038
Primary Topic
Growth Hormone and Insulin-like Growth Factors
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Nonclinical Validation of the NexPTM Half-Life Extension Platform Using Human Growth Hormone as a Model Therapeutic Protein

Changkwon Song, Sang Mee Lee, Hye-Shin Chung, Jeong Soo Cho et al.
Molecular Pharmaceutics
Growth Hormone and Insulin-like Growth Factors
article

Nonclinical Validation of the NexPTM Half-Life Extension Platform Using Human Growth Hormone as a Model Therapeutic Protein

Changkwon Song, Sang Mee Lee, Hye-Shin Chung, Jeong Soo Cho, Sun-Ah You, Yi Jin Song, Ji-Sun Kim, Jinhee Lee, Jaehyeong Ko, Sang Hee Lee, Kyuwan Kim, Kibum Park, Tae-Yon Chun, Ji Eun Hong, Minsoo Byun, Soon Jae Park
article en

Abstract

Abstract NexP™ is a proprietary carrier platform engineered from human alpha-1 antitrypsin (A1AT) to extend the systemic exposure of therapeutic proteins while retaining biological activity. The NexP™ scaffold incorporates an additional N-linked glycosylation site and a mutation in the reactive center loop designed to reduce its intrinsic protease inhibitory activity. Human growth hormone (hGH) was selected as a model therapeutic protein to evaluate the pharmacological performance, safety profile, and developability of the NexP™ platform. ALT-P1, a long-acting hGH candidate, containing NexP™ at its C-terminus of hGH, was produced in mammalian cells and purified by a series of column chromatography steps. The purified protein was characterized Human growth hormone (hGH) was selected as a model therapeutic protein to evaluate the pharmacological properties, nonclinical safety, and developability of this platform. ALT-P1, an hGH fusion protein containing NexP™ at its C-terminus, was produced in mammalian cells and purified using chromatographic methods. ALT-P1 was characterized by physicochemical analyses, including SDS-PAGE, isoelectric focusing, size-exclusion chromatography, N-linked glycan profiling, and circular dichroism (CD) spectroscopy. Binding affinity for the human growth hormone receptor and in vitro activity were further assessed by receptor-binding, MTS-based cell proliferation and luciferase reporter assays. Pharmacokinetic, pharmacodynamic, and toxicological profiles were evaluated in Sprague-Dawley rats and cynomolgus monkeys. Systemic exposure to ALT-P1 increased with increasing subcutaneous doses in rats, and pharmacokinetic studies demonstrated sustained systemic exposure in both species. ALT-P1 increased serum insulin-like growth factor I (IGF-1) levels in cynomolgus monkeys and promoted body weight gain and tibial growth in hypophysectomized rats. In a 26 week repeated-dose toxicity study in cynomolgus monkeys, ALT-P1 was generally well tolerated, with a no-observed-adverse-effect level (NOAEL) of 20 mg/kg, the highest dose tested. A GMP-manufactured clinical batch maintained its quality attributes and biological potency during long-term storage. Collectively, these findings support the further development of ALT-P1 as a long-acting hGH candidate and suggest the potential applicability of NexP™ as a half-life-extension platform for other biologic therapeutics.

Molecular Pharmaceutics
Alteogen (South Korea) (KR)
Korea Evaluation Institute of Industrial Technology
Good health and well-being
Growth Hormone and Insulin-like Growth Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon